Evaluation and management of steroid-sensitive nephrotic syndrome

Curr Opin Pediatr. 2008 Apr;20(2):145-50. doi: 10.1097/MOP.0b013e3282f4307a.


Purpose of review: This review examines new literature published in 2006 and 2007 on steroid-sensitive nephrotic syndrome.

Recent findings: Steroid-sensitive nephrotic syndrome has long been thought to be due to lymphocyte-derived circulating factors leading to podocyte injury with subsequent proteinuria. New studies support this mechanism and implicate the T helper 2 cytokine IL-13. In addition a genetic mutation in familial nephrotic syndrome has been reported in a child, who responded to corticosteroid therapy. There are new clinical trial data supporting the efficacy of levamisole in steroid-sensitive nephrotic syndrome and preliminary trial data on mycophenolate mofetil supporting its efficacy as a steroid-sparing agent. Case reports support the use of the B cell-depleting antibody rituximab in steroid-sensitive nephrotic syndrome. Finally there is a meta-analysis of six studies suggesting an increase in the incidence of focal and segmental glomerulosclerosis in steroid-sensitive nephrotic syndrome over the last 20 years.

Summary: Progress has been made towards elucidating the cause of steroid-sensitive nephrotic syndrome. Data from adequately powered randomized controlled trials are still required to evaluate therapies for frequently relapsing and steroid-dependent steroid-sensitive nephrotic syndrome.

Publication types

  • Review

MeSH terms

  • Animals
  • Child
  • Cyclophosphamide / therapeutic use
  • Cyclosporine / therapeutic use
  • Glucocorticoids / therapeutic use*
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Mycophenolic Acid / analogs & derivatives
  • Mycophenolic Acid / therapeutic use
  • Nephrotic Syndrome / drug therapy*
  • Nephrotic Syndrome / epidemiology
  • Nephrotic Syndrome / etiology
  • Treatment Outcome


  • Glucocorticoids
  • Immunosuppressive Agents
  • Cyclosporine
  • Cyclophosphamide
  • Mycophenolic Acid